Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Daily Dosing for Bedaquiline in Patients with Tuberculosis.

Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann DJ.

Antimicrob Agents Chemother. 2019 Aug 26. pii: AAC.00463-19. doi: 10.1128/AAC.00463-19. [Epub ahead of print]


Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.

Salinger DH, Subramoney V, Everitt D, Nedelman JR.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00907-19. doi: 10.1128/AAC.00907-19. Print 2019 Oct.


Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.

Li H, Salinger DH, Everitt D, Li M, Del Parigi A, Mendel C, Nedelman JR.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00445-19. doi: 10.1128/AAC.00445-19. Print 2019 Oct.


Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases.

Li H, Köck K, Wisler JA, Rees WA, Prince PJ, Reynhardt KO, Hsu H, Yu Z, Borie DC, Salinger DH, Pan WJ.

Pharmacol Res Perspect. 2015 Feb;3(1):e00098. doi: 10.1002/prp2.98. Epub 2014 Dec 9.


Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

McCune JS, Vicini P, Salinger DH, O'Donnell PV, Sandmaier BM, Anasetti C, Mager DE.

Cancer Chemother Pharmacol. 2015 Jan;75(1):67-75. doi: 10.1007/s00280-014-2618-2. Epub 2014 Nov 6.


A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.

Salinger DH, Endres CJ, Martin DA, Gibbs MA.

Clin Pharmacol Drug Dev. 2014 Jul;3(4):276-83. doi: 10.1002/cpdd.103. Epub 2014 Feb 18.


Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.

Endres CJ, Salinger DH, Köck K, Gastonguay MR, Martin DA, Klekotka P, Nirula A, Gibbs MA.

J Clin Pharmacol. 2014 Nov;54(11):1230-8. doi: 10.1002/jcph.334. Epub 2014 May 27.


Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.

Russell CB, Rand H, Bigler J, Kerkof K, Timour M, Bautista E, Krueger JG, Salinger DH, Welcher AA, Martin DA.

J Immunol. 2014 Apr 15;192(8):3828-36. doi: 10.4049/jimmunol.1301737. Epub 2014 Mar 19.


Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.

Dodds MG, Salinger DH, Mandema J, Gibbs JP, Gibbs MA.

CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2:e58. doi: 10.1038/psp.2013.32.


Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous regimens equivalent? A population pharmacokinetic study.

Salinger DH, Mundle S, Regi A, Bracken H, Winikoff B, Vicini P, Easterling T.

BJOG. 2013 Jun;120(7):894-900. doi: 10.1111/1471-0528.12222. Epub 2013 Mar 26.


Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA.

J Invest Dermatol. 2012 Oct;132(10):2466-2469. doi: 10.1038/jid.2012.163. Epub 2012 May 24. No abstract available.


A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients.

Li H, Mager DE, Bemer MJ, Salinger DH, Vicini P, Sandmaier BM, Nash R, McCune JS.

J Clin Pharmacol. 2012 Nov;52(11):1654-64. doi: 10.1177/0091270011429567. Epub 2011 Dec 14.


A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.

Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA.

Clin Pharmacol Ther. 2011 Dec;90(6):828-35. doi: 10.1038/clpt.2011.256. Epub 2011 Nov 2.


Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA.

Clin Pharmacokinet. 2011 Feb;50(2):131-42. doi: 10.2165/11537430-000000000-00000.


Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics.

Tomazela DM, Patterson BW, Hanson E, Spence KL, Kanion TB, Salinger DH, Vicini P, Barret H, Heins HB, Cole FS, Hamvas A, MacCoss MJ.

Anal Chem. 2010 Mar 15;82(6):2561-7. doi: 10.1021/ac1001433.


Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.

Salinger DH, Vicini P, Blough DK, O'Donnell PV, Pawlikowski MA, McCune JS.

J Clin Pharmacol. 2010 Nov;50(11):1292-300. doi: 10.1177/0091270009357430. Epub 2010 Jan 14.


Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.

Salinger DH, Shen DD, Thummel K, Wittkowsky AK, Vicini P, Veenstra DL.

Pharmacogenet Genomics. 2009 Dec;19(12):965-71. doi: 10.1097/FPC.0b013e3283333b80.


A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.

Salinger DH, Blough DK, Vicini P, Anasetti C, O'Donnell PV, Sandmaier BM, McCune JS.

Clin Cancer Res. 2009 Aug 15;15(16):5280-7. doi: 10.1158/1078-0432.CCR-09-0427. Epub 2009 Aug 11.


Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration.

Li M, Andrew MA, Wang J, Salinger DH, Vicini P, Grady RW, Phillips B, Shen DD, Anderson GD.

Antimicrob Agents Chemother. 2009 Jul;53(7):2725-32. doi: 10.1128/AAC.00774-08. Epub 2009 Apr 27.


Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.

McCune JS, Batchelder A, Guthrie KA, Witherspoon R, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB.

Clin Pharmacol Ther. 2009 Jun;85(6):615-22. doi: 10.1038/clpt.2009.27. Epub 2009 Mar 18.


Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.

McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR.

J Clin Pharmacol. 2009 Jan;49(1):88-102. doi: 10.1177/0091270008325928. Epub 2008 Oct 16.


Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics.

Lynn AM, Bradford H, Kantor ED, Seng KY, Salinger DH, Chen J, Ellenbogen RG, Vicini P, Anderson GD.

Anesth Analg. 2007 May;104(5):1040-51, tables of contents.


Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach.

Salinger DH, McCune JS, Ren AG, Shen DD, Slattery JT, Phillips B, McDonald GB, Vicini P.

Clin Cancer Res. 2006 Aug 15;12(16):4888-98.

Supplemental Content

Loading ...
Support Center